$ENVA

Fisher David sold $6.6M of ENVA

Fisher David (Executive Chairman) sold 28,500 shares of Enova International, Inc. (ENVA) at an average of $231.49 ($231.45–$231.51, $6.60M total) across 2 trades over 2026-07-14 to 2026-07-15 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Fisher David
Published Jul 16, 2026, 8:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 16, 2026, 8:33 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$ENVA
Neutral
medium confidence
Mentioned
$ENVA
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ENVANeutralLow
01

Why it matters

The disclosure updates the insider’s post-sale holdings and confirms the sale was executed via an open-market transaction under a pre-arranged 10b5-1 plan.

02

Market read

This is a routine insider-sale filing with limited incremental fundamental information due to the 10b5-1 plan.

03

What to watch

Traders may overreact to insider sales; the key differentiator here is the explicitly stated pre-arranged 10b5-1 plan, which often reduces informational content.

Relevance 5/10Novelty 4/10Timing: SEC Form 4 filed 2026-07-16 after-hours.

Background

The article is an SEC Form 4 insider transaction disclosure for Enova International, Inc.

Company-level read

Ticker impact

$ENVANeutralMedium confidence
Context

Enova executive chairman David Fisher sold 28,500 shares in open-market trades for about $6.6M under a 10b5-1 plan.

Expected impact

Likely limited near-term impact; any reaction should be muted given the 10b5-1 structure.

Evidence & confidence

The filing provides exact trade dates, share count, and value, but the presence of a pre-arranged 10b5-1 plan typically lowers interpretive weight for fundamentals.

Market effects

Minimal, as this is a single-company insider transaction without sector-wide disclosures.

None indicated.

None indicated.

Counterpoint

Because the sale is under a 10b5-1 plan, it may reflect routine liquidity needs rather than a bearish view on Enova’s prospects.

Key entities

  • Enova International, Inc.

    Company whose executive chairman reported open-market share sales on Form 4.

  • Fisher David

    Executive Chairman and officer/director who sold shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ENVAMedAI 8/10

Enova International subsidiary announces $500 million asset-backed notes offering

Enova International's subsidiary plans a $500M asset-backed notes offering, with four classes of notes ranging from 5.61% to 8.28% interest. The notes are backed by small business loans and expected to be rated by Kroll. Enova reported strong Q2 2026 earnings, exceeding estimates, but withdrew a bank acquisition due to regulatory challenges. Citizens lowered its price target to $215, maintaining an Outperform rating.

$ENVAMedAI 8/10

Enova to issue $500.026M Series 2026-1 asset-backed notes backed by OnDeck loans

Enova plans to issue $500.026M in asset-backed notes due 2026, secured by OnDeck small business loans. The notes, divided into four classes, have fixed rates ranging from 5.61% to 8.28%. KBRA is expected to rate the notes AA(sf) to BB(sf). The proceeds will be used to purchase loans from OnDeck and fund a reserve account. The offering is targeted at qualified institutional buyers under Rule 144A and offshore under Regulation S, with a closing date around September 25, 2026, subject to conditions